INIM0031: Neoplasia and its Treatment

View Online

1.

Weinberg RA. The Biology of Cancer. 2nd ed. Garland Science; 2014.

2.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. doi:10.1016/S0092-8674(00)81683-9

3.

Lazebnik Y. What are the hallmarks of cancer? Nature Reviews Cancer. 2010;10(4):232-233. doi:10.1038/nrc2827

4.

Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer. 2015;16(1):35-42. doi:10.1038/nrc.2015.4

5.

Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer. 2015;16(1):20-33. doi:10.1038/nrc.2015.2

6.

Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107-1111. doi:10.1038/35074122

7.

Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903-907. doi:10.1038/nature06309

8.

Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466

9.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. Science. 2011;331(6024):1565-1570. http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents

10.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine. 2012;366(26):2443-2454. doi:10.1056/NEJMoa1200690

11.

Grupp SA, Kalos M, Barrett D, et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine. 2013;368(16):1509-1518. doi:10.1056/NEJMoa1215134

12.

Robbins PF, Morgan RA, Feldman SA, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology. 2011;29(7):917-924. doi:10.1200/JCO.2010.32.2537

13.

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. doi:10.1126/science.aaa4971

14.

Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine. 2016;22(1):26-36. doi:10.1038/nm.4015

15.

Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood. 2016;127(26):3305-3311. doi:10.1182/blood-2015-11-629071

16.

de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 2012;13(6):607-615. doi:10.1016/S1470-2045(12)70137-7

17.

zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384(2):260-265. doi:10.1016/j.virol.2008.11.046

18.

Ajila V, Shetty H, Babu S, Shetty V, Hegde S. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. Journal of Sexually Transmitted Diseases. 2015;2015:1-5. doi:10.1155/2015/791024

19.

Spurgeon ME, Lambert PF. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology. 2013;435(1):118-130. doi:10.1016/j.virol.2012.09.029

20.

Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell polyomavirus. Current Opinion in Virology. 2015;11:38-43. doi:10.1016/j.coviro.2015.01.009

21.

Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clinical Microbiology and Infection. 2015;21(11):969-974. doi:10.1016/j.cmi.2015.06.026

22.

Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine. 2015;8(9). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/

23.

Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. The Journal of Experimental Medicine. 2011;208(12):2351-2355. doi:10.1084/jem.20112160

24.

Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30(12):1379-1389. doi:10.1038/onc.2010.537

25.

Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. Clinical Microbiology and Infection. 2015;21(11):975-983. doi:10.1016/j.cmi.2015.07.009

26.

Reichert JM. Antibodies to watch in 2017. mAbs. 2017;9(2):167-181. doi:10.1080/19420862.2016.1269580

27.

Reichert JM. Antibodies to watch in 2016. mAbs. 2016;8(2):197-204. doi:10.1080/19420862.2015.1125583

28.

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9-14. doi:10.4161/19420862.2015.989042

29.

Reichert JM. Marketed therapeutic antibodies compendium. mAbs. 2012;4(3):413-415. doi:10.4161/mabs.19931

30.

Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy. 2002;9(12):967-978. doi:10.1038/sj.cgt.7700537

31.

Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nature Biotechnology. 2012;30(7):658-670. doi:10.1038/nbt.2287

32.

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery. 2015;14(9):642-662. doi:10.1038/nrd4663

33.

Larson C, Oronsky B, Scicinski J, et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6(24). doi:10.18632/oncotarget.5116

34.

Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the

T cell response. Nature Reviews Immunology. 2012;12(4):269-281. doi:10.1038/nri3191

35.

Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews. 2015;263(1):68-89. doi:10.1111/imr.12243

36.

Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. The Journal of Immunology. 2015;195(3):755-761. doi:10.4049/jimmunol.1500751

37.

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer. 2012;12(4):265-277. doi:10.1038/nrc3258